Also: Trump pledges to invest in AI for pediatric cancer care, after massive funding cutsOctober 3, 2025Check out STAT+Sponsored By Adobe STAT+ | Trump administration delays effort to address Medicare drug price negotiation loophole While Trump presses pharma companies to lower their prices, he rarely mentions that Medicare already negotiates drug prices, thanks to Biden. By John Wilkerson STAT+ | The biotech scorecard for the fourth quarter: 36 stock-moving events to watch Here's a look at top trial readouts and FDA drug approval decisions for Summit Therapeutics, BridgeBio, and other biotech companies. By Adam Feuerstein STAT+ | Fights over Tylenol, SSRIs highlight the enduring lack of pregnant women in drug trials Shutting pregnant women out of clinical trials to protect them and their babies has had the opposite effect, experts say. By Lizzy Lawrence Melissa Brower/Centers for Disease Control and Prevention via AP STAT+ | WHO says the antibacterial pipeline reveals a dual crisis: scarcity and lack of innovation Antimicrobial resistance is one of the most urgent global health threats, causing over one million deaths annually By Ed Silverman More around STATIn case you missed it After cuts to research funding, Trump pledges millions for pediatric cancer initiative involving AI, CNN Jazz Pharma, Roche's combination therapy for lung cancer gets US approval, Reuters Penn researchers are testing whether two common generic medications could help kill dormant cancer cells, Philadelphia Inquirer Check out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments